Target intelligence / Profile preview

Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1)

Target
ECH1
Molecular classification
Enzyme, Isomerase, Hydratase/isomerase superfamily
01

Overview

Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1) is an enzyme encoded by the human ECH1 gene that catalyzes the isomerization of 3-trans,5-cis-dienoyl-CoA to 2-trans,4-trans-dienoyl-CoA as part of the auxiliary pathway of fatty acid β-oxidation[1][3][9]. It belongs to the hydratase/isomerase superfamily, localizes primarily to peroxisomes and mitochondria, and helps metabolize unsaturated fatty acids with conjugated double bonds[3]. Altered expression or function of ECH1 has been implicated in metabolic conditions such as adrenoleukodystrophy, steatohepatitis, and myocardial infarction[1][4][7]. The gene product may serve as a biomarker for hepatic disease but is not currently a direct drug target.

Other names
Enoyl-CoA hydratase 1Delta(3,5)-Delta(2,4)-dienoyl-coenzyme A isomerasePeroxisomal enoyl-CoA hydratase 1Dienoyl-CoA isomeraseHPXELEpididymis secretory sperm binding protein
02

Mechanism of action

Not specifically applicable, as ECH1 is not currently a direct drug target. Drugs affecting fatty acid oxidation or peroxisome proliferators may affect ECH1 activity indirectly[4][1].

03

Biological functions

Fatty acid beta-oxidationIsomerization of unsaturated fatty acyl-CoA intermediatesMitochondrial metabolismPeroxisomal metabolism
04

Disease associations

AdrenoleukodystrophyNonalcoholic steatohepatitisApical myocardial infarction(in mouse ortholog) hepatic steatosis, insulin resistance, tumorigenesis[1][4][7][8]
05

Safety considerations

No drug-related safety concerns are currently documented, as no direct therapeutics target ECH1; alteration in activity could theoretically affect lipid metabolism and energy homeostasis[4]
06

Interacting drugs

Not explicitly listed in current results; no FDA-approved drugs identified that directly target ECH1[1][7][9]
07

Biomarkers

ECH1 expression has been identified as a novel biomarker in certain diseases such as nonalcoholic steatohepatitis[4]

Beyond the preview

Go deeper on Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (ECH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call